Loading patent…
AssigneesDana-Farber Cancer Institute, Inc., President and Fellows of Harvard College, Massachusetts Institute of Technology
InventorsEllis L. Reinherz, Kyoung Joon Oh, Mikyung Kim, Gerhard Wagner, Zhen-Yu J. Sun, Darrell J. Irvine, Anna Bershteyn
Estimating the term…
The present disclosure relates to reagents (antigenic and/or immunogenic reagents) and kits that are useful in a variety of in vitro, in vivo, and ex vivo methods including, e.g., methods for inducing an immune response, or for generating an antibody, in a subject. The reagents described herein can be used in the treatment or prevention of HIV-1 infections. In addition, the disclosure provides methods and compositions useful for designing (or identifying) an agent that binds to an membrane proximal external region (MPER) of an HIV-1 gp160 polypeptide or an agent that inhibits the fusion of an HIV-1 particle to a cell.
A reagent comprising:
-5. (canceled)
-14. (canceled)
-18. (canceled)
(canceled)
-23. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
-45. (canceled)
(canceled)
(canceled)
A method for inducing an immune response in a subject, the method comprising administering to a subject a composition comprising lipid and a polypeptide consisting of a membrane proximal external region (MPER) of an HIV-1 gp160 polypeptide,
-63. (canceled)
-71. (canceled)
A method for designing an agent that interacts with a membrane proximal external region (MPER) of an HIV-1 gp160 polypeptide, the method comprising:
-82. (canceled)
A method for identifying a potential inhibitor of the binding of an HIV-1 particle to a cell, the method comprising:
Dependencies are inferred from the claim text.